Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor–Mediated Destruction of Intestinal Epithelial Cells

Gastroenterology

Volumn 152, Issue 4, 2017, Pages 867-879

  Grabinger, Thomas ^a   Bode, Konstantin J ^a   Demgenski, Janine ^a   Seitz, Carina ^a   Delgado, M Eugenia ^a   Kostadinova, Feodora ^a   Reinhold, Cindy ^a   Etemadi, Nima ^b,c   Wilhelm, Sabine ^d   Schweinlin, Matthias ^d   Hänggi, Kay ^e   Knop, Janin ^e   Hauck, Christof ^a   Walles, Heike ^d,f   Silke, John ^b,c   Wajant, Harald ^d   Nachbur, Ueli ^b,c   W Wei Lynn, Wong ^e   Brunner, Thomas ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB   (Germany)

Author keywords

IBD; Mouse Model; TNF Signaling; TWEAK

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE 3; INHIBITOR OF APOPTOSIS PROTEIN 1; RNA; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR; X LINKED INHIBITOR OF APOPTOSIS; BIRC2 PROTEIN, HUMAN; BIRC2 PROTEIN, MOUSE; BIRC3 PROTEIN, MOUSE; BIRC4 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; THIAZOLE DERIVATIVE; TNFRSF1A PROTEIN, MOUSE; TNFSF12 PROTEIN, HUMAN; TNFSF12 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UBIQUITIN PROTEIN LIGASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; APOPTOSIS; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE CRYPT; INTESTINE EPITHELIUM CELL; INTESTINE TISSUE; MACROPHAGE; MOUSE; NONHUMAN; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RAW 264.7 CELL LINE; REGULATORY MECHANISM; YOUNG ADULT; ANIMAL; C57BL MOUSE; CELL DEATH; CYTOLOGY; CYTOPLASM; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; INTESTINE MUCOSA; KNOCKOUT MOUSE; LIVER; METABOLISM; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; EPITHELIAL CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTESTINAL MUCOSA; LIVER; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGANOIDS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; TUMOR NECROSIS FACTORS; UBIQUITIN-PROTEIN LIGASES;

EID: 85010949209     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.11.019     Document Type: Article

References (65)

1. 1 Corazza, N., Eichenberger, S., Eugster, H.P., et al. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells. J Exp Med 190 (1999), 1479–1492.
2. 2 Roulis, M., Armaka, M., Manoloukos, M., et al. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci U S A 108 (2011), 5396–5401.
3. 3 Mannel, D.N., Echtenacher, B., TNF in the inflammatory response. Chem Immunol 74 (2000), 141–161.
4. 4 Wajant, H., Pfizenmaier, K., Scheurich, P., Tumor necrosis factor signaling. Cell Death Differ 10 (2003), 45–65.
5. 5 Hayden, M.S., West, A.P., Ghosh, S., NF-kappaB and the immune response. Oncogene 25 (2006), 6758–6780.
6. 6 Maloy, K.J., Powrie, F., Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474 (2011), 298–306.
7. 7 Sode, J., Vogel, U., Bank, S., et al. Anti-TNF treatment response in rheumatoid arthritis patients is associated with genetic variation in the NLRP3-inflammasome. PLoS One, 9, 2014, e100361.
8. 8 Carswell, E.A., Old, L.J., Kassel, R.L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72 (1975), 3666–3670.
9. 9 Walczak, H., Krammer, P.H., The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256 (2000), 58–66.
10. 10 Van Antwerp, D.J., Martin, S.J., Kafri, T., et al. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274 (1996), 787–789.
11. 11 Beg, A.A., Baltimore, D., An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274 (1996), 782–784.
12. 12 Piguet, P.F., Vesin, C., Donati, Y., et al. TNF-induced enterocyte apoptosis and detachment in mice: induction of caspases and prevention by a caspase inhibitor, ZVAD-fmk. Lab Invest 79 (1999), 495–500.
13. 13 Piguet, P.F., Grau, G.E., Allet, B., et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med 166 (1987), 1280–1289.
14. 14 Kim, J.M., Eckmann, L., Savidge, T.C., et al. Apoptosis of human intestinal epithelial cells after bacterial invasion. J Clin Invest 102 (1998), 1815–1823.
15. 15 Liu, F., Feuer, R., Hassett, D.E., et al. Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8 T cell-mediated, TNF-dependent immunopathology. J Clin Invest 116 (2006), 465–475.
16. 16 Leppkes, M., Roulis, M., Neurath, M.F., et al. Pleiotropic functions of TNF-alpha in the regulation of the intestinal epithelial response to inflammation. Intl Immunol 26 (2014), 509–515.
17. 17 Neurath, M.F., Fuss, I., Pasparakis, M., et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol, 27, 1997 1743–1450.
18. 18 Gyrd-Hansen, M., Meier, P., IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10 (2010), 561–574.
19. 19 Silke, J., Vucic, D., IAP family of cell death and signaling regulators. Methods Enzymol 545 (2014), 35–65.
20. 20 Mahoney, D.J., Cheung, H.H., Mrad, R.L., et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A 105 (2008), 11778–11783.
21. 21 Varfolomeev, E., Goncharov, T., Maecker, H., et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal, 5, 2012, ra22.
22. 22 Bertrand, M.J., Milutinovic, S., Dickson, K.M., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 30 (2008), 689–700.
23. 23 Vince, J.E., Pantaki, D., Feltham, R., et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b and to prevent tnf-induced apoptosis. J Biol Chem 284 (2009), 35906–35915.
24. 24 Li, L., Thomas, R.M., Suzuki, H., et al. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305 (2004), 1471–1474.
25. 25 Vince, J.E., Wong, W.W., Khan, N., et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131 (2007), 682–693.
26. 26 Varfolomeev, E., Blankenship, J.W., Wayson, S.M., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131 (2007), 669–681.
27. 27 Silke, J., Vaux, D.L., IAP gene deletion and conditional knockout models. Semin Cell Dev Biol 39 (2015), 97–105.
28. 28 Vince, J.E., Chau, D., Callus, B., et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 182 (2008), 171–184.
29. 29 Wicovsky, A., Salzmann, S., Roos, C., et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ 16 (2009), 1445–1459.
30. 30 Jost, P.J., Grabow, S., Gray, D., et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 460 (2009), 1035–1039.
31. 31 Moulin, M., Anderton, H., Voss, A.K., et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J 31 (2012), 1679–1691.
32. 32 Whitehead, R.H., VanEeden, P.E., Noble, M.D., et al. Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc Natl Acad Sci U S A 90 (1993), 587–591.
33. 33 Roos, C., Wicovsky, A., Muller, N., et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J Immunol 185 (2010), 1593–1605.
34. 34 Muller-Sienerth, N., Dietz, L., Holtz, P., et al. SMAC mimetic BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells. PLoS One, 6, 2011, e21556.
35. 35 Grabinger, T., Luks, L., Kostadinova, F., et al. Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy. Cell Death Dis, 5, 2014, e1228.
36. 36 Schweinlin, M., Wilhelm, S., Schwedhelm, I., et al. Development of an advanced primary human in vitro model of the small intestine. Tissue Eng Part C Methods 22 (2016), 873–883.
37. 37 Feltham, R., Moulin, M., Vince, J.E., et al. Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. J Biol Chem 285 (2010), 17525–17536.
38. 38 Jakob, S., Corazza, N., Diamantis, E., et al. Detection of apoptosis in vivo using antibodies against caspase-induced neo-epitopes. Methods 44 (2008), 255–261.
39. 39 Suenaert, P., Bulteel, V., Lemmens, L., et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97 (2002), 2000–2004.
40. 40 Peschon, J.J., Torrance, D.S., Stocking, K.L., et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160 (1998), 943–952.
41. 41 Sato, T., Vries, R.G., Snippert, H.J., et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459 (2009), 262–265.
42. 42 Piguet, P.F., Vesin, C., Guo, J., et al. TNF-induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53. Eur J Immunol 28 (1998), 3499–3505.
43. 43 Noti, M., Corazza, N., Mueller, C., et al. TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med 207 (2010), 1057–1066.
44. 44 Yabal, M., Muller, N., Adler, H., et al. XIAP restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep 7 (2014), 1796–1808.
45. 45 Kawashima, R., Kawamura, Y.I., Oshio, T., et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology 141 (2011), 2119–2129 e8.
46. 46 Son, A., Oshio, T., Kawamura, Y.I., et al. TWEAK/Fn14 pathway promotes a T helper 2-type chronic colitis with fibrosis in mice. Mucosal Immunol 6 (2013), 1131–1142.
47. 47 Geserick, P., Hupe, M., Moulin, M., et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol 187 (2009), 1037–1054.
48. 48 Silke, J., Meier, P., Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harbor Perspect Biol., 5, 2013.
49. 49 Nielsen, O.H., New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne), 1, 2014, 3.
50. 50 Atreya, R., Neurath, M.F., New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 1 (2008), 175–182.
51. 51 Ma, T.Y., Boivin, M.A., Ye, D., et al. Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 288 (2005), G422–G430.
52. 52 Van Hauwermeiren, F., Armaka, M., Karagianni, N., et al. Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium. J Clin Invest 123 (2013), 2590–2603.
53. 53 Kaiser, W.J., Upton, J.W., Long, A.B., et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471 (2011), 368–372.
54. 54 Dillon, C.P., Weinlich, R., Rodriguez, D.A., et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 157 (2014), 1189–1202.
55. 55 Welz, P.S., Wullaert, A., Vlantis, K., et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature 477 (2011), 330–334.
56. 56 Rickard, J.A., O'Donnell, J.A., Evans, J.M., et al. RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157 (2014), 1175–1188.
57. 57 Dannappel, M., Vlantis, K., Kumari, S., et al. RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis. Nature 513 (2014), 90–94.
58. 58 Takahashi, N., Vereecke, L., Bertrand, M.J., et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature 513 (2014), 95–99.
59. 59 Gentle, I.E., Wong, W.W., Evans, J.M., et al. In TNF-stimulated cells, RIPK1 promotes cell survival by stabilizing TRAF2 and cIAP1, which limits induction of non-canonical NF-kappaB and activation of caspase-8. The Journal of biological chemistry 286 (2011), 13282–13291.
60. 60 Damgaard, R.B., Gyrd-Hansen, M., Inhibitor of apoptosis (IAP) proteins in regulation of inflammation and innate immunity. Discov Med 11 (2011), 221–231.
61. 61 Damgaard, R.B., Nachbur, U., Yabal, M., et al. The ubiquitin ligase XIAP recruits LUBAC for NOD2 signaling in inflammation and innate immunity. Mol Cell 46 (2012), 746–758.
62. 62 Ogura, Y., Bonen, D.K., Inohara, N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001), 603–606.
63. 63 Pedersen, J., LaCasse, E.C., Seidelin, J.B., et al. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation. Trends Mol Med 20 (2014), 652–665.
64. 64 Bertrand, M.J., Doiron, K., Labbe, K., et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30 (2009), 789–801.
65. 65 Dohi, T., Burkly, L.C., The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukocyte Biol 92 (2012), 265–279.